Investment Bank (EIB) is providing a €45 million loan to part-finance
HIPRA's investments, working capital requirements and research, development and
innovation activities for developing a new COVID-19 vaccine.
HIPRA is a
pharmaceutical company focusing on the development, manufacture and sale of
vaccines and other immunological solutions for both animals and humans. The
COVID-19 pandemic has accelerated the company’s entry into the human health
sector thanks to its extensive knowledge and skills in working on the
development of a COVID-19 vaccine.
project will strengthen HIPRA's knowledge and production capacity for coping
with current and future pandemics. It will also help to secure a European
supply chain for the commercial manufacture of a vaccine based on innovative
recombinant protein technology.
this project, the EIB will help to build scientific knowledge at a European
level, while also safeguarding and promoting highly skilled job opportunities.
This is the EIB's second loan to HIPRA, after an initial €35 million
financing operation signed in two tranches in 2019 and 2021.
EIB Vice-President Ricardo Mourinho Félix said: “We
are very proud to be working with HIPRA once again, this time for something of
such paramount importance as a COVID-19 vaccine. The operation demonstrates the
EIB's firm commitment to incentivising innovative skills in health sector
companies and to improving people's quality of life.”
“The entire HIPRA team is committed to
developing the new COVID-19 vaccine. We believe that this project will also
help to strengthen a strategic capacity for Europe, enabling it to face new
challenges in the future. The EIB is supporting this vision.”
The European Investment Bank (ElB) is the
long-term lending institution of the European Union owned by its Member States.
It makes long-term finance available for sound investment in order to
contribute towards EU policy objectives.
and medium-sized enterprises (SMEs) and driving innovation are among the EIB
Group’s key priorities in Spain, and the Bank allocated over
€4.195 billion and €878 million, respectively, to these goals in
HIPRA is a pharmaceutical company focused on
prevention and diagnosis for animal and human health, with a wide range of
highly innovative vaccines and advanced diagnostic services. It is dedicated to
offering solutions that improve global health. HIPRA has a strong international
presence in more than 39 countries with its own subsidiaries, 11 diagnostic
centres and two production plants. Research and development form the core of
its knowledge — it allocates 10% of its annual turnover to R&D.